Report Thumbnail
Product Code LP0911912527ST
Published Date 2026/3/5
LP Information
English76 PagesGlobal

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth (Status and Outlook) 2026-2032 ‐ Pharmaceutical / LifeSciense Market


Report Thumbnail
Product Code LP0911912527ST◆An updated version may be available. We will check for you.
Published Date 2026/3/5
LP Information
English 76 PagesGlobal

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Growth (Status and Outlook) 2026-2032 ‐ Pharmaceutical / LifeSciense Market


Abstract

This report provides a comprehensive analysis of the global Phosphorodiamidate Morpholino Oligomers (PMO) drug market, projecting significant growth through 2032. Highlighting their ability to regulate target genes via splicing conversion and translation blocking, PMO drugs are primarily utilized for treating Duchenne muscular dystrophy. The study evaluates key market dynamics, regional trends across the Americas, APAC, and Europe, and competitive landscapes involving major players like Sarepta Therapeutics and Avidity Biosciences, segmented by type and application.

Related Questions

Sarepta Therapeutics, Inc, NS Pharma, Inc., Nippon Shinyaku, Dyne, Avidity Biosciences

regulate target genes at splicing conversion and translation level blocking

Summary

Executive Overview

The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is projected to experience significant growth from 2025 through 2032, maintaining a steady compound annual growth rate throughout the forecast period.

Product Profile & Therapeutic Advantages

PMO drugs offer a distinct advantage through their ability to regulate target genes at two specific levels:

  • Splicing conversion
  • Translation level blocking

Currently, these drugs are primarily utilized in the treatment of Duchenne muscular dystrophy.

Market Forecast & Regional Analysis

The LPI (LP Information) research report, titled “PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Forecast,” reviews total global sales in 2025 and provides a comprehensive analysis of projected sales from 2026 through 2032. The report provides detailed analysis in US$ millions, broken down by region, market sector, and sub-sector.

Regional Market Trends

  • Global Market: The market is expected to expand significantly between 2025 and 2032.
  • United States: The market is estimated to increase from 2025 through 2032.
  • China: The market is estimated to increase from 2025 through 2032.
  • Europe: The market is estimated to increase from 2025 through 2032.

Market Segmentation

By Type

  • DMD exon 51 Based
  • DMD exon 53 Based
  • DMD exon 45 Based
  • Other

By Application

  • Hospital
  • Clinic

By Geography

  • Americas: United States, Canada, Mexico, Brazil
  • APAC: China, Japan, Korea, Southeast Asia, India, Australia
  • Europe: Germany, France, UK, Italy, Russia
  • Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

This report highlights key trends related to company formation, revenue, market share, latest developments, and M&A activity. It analyzes the strategies of leading global companies, focusing on their PMO (Phosphorodiamidate Morpholino Oligomers) Drug portfolios, capabilities, market entry strategies, market positions, and geographic footprints.

Key Market Players

The following companies have been profiled based on primary expert input and analysis of their coverage, product portfolio, and market penetration:

  • Sarepta Therapeutics, Inc
  • NS Pharma, Inc.
  • Nippon Shinyaku
  • Dyne
  • Avidity Biosciences

Market Concentration: In 2025, the two largest global companies held a significant portion of the total market revenue share.

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats

  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (2021-2032)
      • 2.1.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
      • 2.1.3 World Current & Future Analysis for PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Country/Region (2021, 2025 & 2032)
    • 2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type
      • 2.2.1 DMD exon 51 Based
      • 2.2.2 DMD exon 53 Based
      • 2.2.3 DMD exon 45 Based
      • 2.2.4 Other
      • 2.2.5 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
        • 2.2.5.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
        • 2.2.5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Market Share by Type (2021-2026)
    • 2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application
      • 2.3.1 Hospital
      • 2.3.2 Clinic
      • 2.3.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
        • 2.3.3.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
        • 2.3.3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Market Share by Application (2021-2026)

  • 3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Player

    • 3.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Market Share by Player
      • 3.1.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Player (2021-2026)
      • 3.1.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Player (2021-2026)
    • 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion

  • 4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Region

    • 4.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026)
    • 4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Annual Revenue by Country/Region (2021-2026)
    • 4.3 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth (2021-2026)
    • 4.4 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth (2021-2026)
    • 4.5 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth (2021-2026)
    • 4.6 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth (2021-2026)

  • 5 Americas

    • 5.1 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
    • 5.2 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
    • 5.3 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil

  • 6 APAC

    • 6.1 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026)
    • 6.2 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
    • 6.3 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia

  • 7 Europe

    • 7.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Country (2021-2026)
    • 7.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
    • 7.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia

  • 8 Middle East & Africa

    • 8.1 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Region (2021-2026)
    • 8.2 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type (2021-2026)
    • 8.3 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application (2021-2026)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries

  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends

  • 10 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Forecast

    • 10.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Region (2027-2032)
      • 10.1.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Region (2027-2032)
      • 10.1.2 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.1.3 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.1.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.1.5 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
    • 10.2 Americas PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Country (2027-2032)
      • 10.2.1 United States Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.2.2 Canada Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.2.3 Mexico Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.2.4 Brazil Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
    • 10.3 APAC PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Region (2027-2032)
      • 10.3.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Forecast
      • 10.3.2 Japan Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.3.3 Korea Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.3.4 Southeast Asia Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.3.5 India Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.3.6 Australia Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
    • 10.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Country (2027-2032)
      • 10.4.1 Germany Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.4.2 France Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.4.3 UK Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.4.4 Italy Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.4.5 Russia Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
    • 10.5 Middle East & Africa PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Region (2027-2032)
      • 10.5.1 Egypt Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.5.2 South Africa Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.5.3 Israel Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
      • 10.5.4 Turkey Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast
    • 10.6 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Type (2027-2032)
    • 10.7 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast by Application (2027-2032)
      • 10.7.1 GCC Countries Market PMO (Phosphorodiamidate Morpholino Oligomers) Drug Forecast

  • 11 Key Players Analysis

    • 11.1 Sarepta Therapeutics, Inc
      • 11.1.1 Sarepta Therapeutics, Inc Company Information
      • 11.1.2 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Offered
      • 11.1.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Gross Margin and Market Share (2021-2026)
      • 11.1.4 Sarepta Therapeutics, Inc Main Business Overview
      • 11.1.5 Sarepta Therapeutics, Inc Latest Developments
    • 11.2 NS Pharma, Inc.
      • 11.2.1 NS Pharma, Inc. Company Information
      • 11.2.2 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Offered
      • 11.2.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Gross Margin and Market Share (2021-2026)
      • 11.2.4 NS Pharma, Inc. Main Business Overview
      • 11.2.5 NS Pharma, Inc. Latest Developments
    • 11.3 Nippon Shinyaku
      • 11.3.1 Nippon Shinyaku Company Information
      • 11.3.2 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Offered
      • 11.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Gross Margin and Market Share (2021-2026)
      • 11.3.4 Nippon Shinyaku Main Business Overview
      • 11.3.5 Nippon Shinyaku Latest Developments
    • 11.4 Dyne
      • 11.4.1 Dyne Company Information
      • 11.4.2 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Offered
      • 11.4.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Gross Margin and Market Share (2021-2026)
      • 11.4.4 Dyne Main Business Overview
      • 11.4.5 Dyne Latest Developments
    • 11.5 Avidity Biosciences
      • 11.5.1 Avidity Biosciences Company Information
      • 11.5.2 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Offered
      • 11.5.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue, Gross Margin and Market Share (2021-2026)
      • 11.5.4 Avidity Biosciences Main Business Overview
      • 11.5.5 Avidity Biosciences Latest Developments

  • 12 Research Findings and Conclusion

USD 7,320 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.